The name Neoteryx is derived from the word neoteric, meaning new or modern, and conveys the new start-up’s mission to deliver novel microsampling products that provide less invasive, simpler, and cost-effective solutions for collecting and testing biological samples.
Four years of internal research and development coupled with a co-development program with major American and European pharmaceutical companies resulted in the revolutionaryVolumetric Absorptive Microsampling (VAMS™) technology. This technology and relating intellectual property developed at Phenomenex have been transferred to Neoteryx for the start-up to begin manufacturing products for the collection, handling, and analysis of biological fluids. Neoteryx’s first product release is the patent pending Mitra™ (RUO) Microsampling Device, which collects 10 µL of fluid in seconds without volumetric blood hematocrit bias. Neoteryx will continue to expand the technology portfolio in order to keep its funnel of novel microsampling products full.
“I am excited to introduce Neoteryx, and even more so its novel technologies and products. The Mitra (RUO) Microsampling Device was officially launched at ASMS 2014 in Baltimore, Maryland”, says Mr. Fasha Mahjoor, Neoteryx CEO. “The response was overwhelmingly positive and all indications point to this device revolutionizing and simplifying how biological fluid sampling and analysis is performed. I look forward to the Mitra (RUO) Microsampler and future Neoteryx products making an immediate and lasting impact in the pharmaceutical and clinical industries.”
Neoteryx’s customers do their work across the biological spectrum, working to advance pharmaceutical development, personalized medicine, clinical research, and clinical diagnostics. They will be able to purchase the Mitra (RUO) Microsampling Device through their distributor, Phenomenex. Other partners will be announced in the future that will also service and support these customers through distribution rights for new products developed by Neoteryx.